The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease.

defined as onset of persistent 50% or greater reduction in eGFR according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation compared with baseline, onset of persistent ...

Ozempic, the GLP-1 drug initially approved by the U.S. Food and Drug Administration in 2017 to treat Type 2 diabetes, was recently OK’d to help reduce risks linked to chronic kidney disease (CKD).

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC ...

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

The five stages of chronic kidney disease (CKD) indicate how well the kidneys are working, ranging from stage 1 (mild kidney ...

Carley is a writer, editor and social media professional. Before starting at Forbes Health, she wrote for Sleepopolis and interned at PBS and Nickelodeon. She's a certified sleep science coach and ...

Medscape Medical News, February 05, 2025 Alert Ozempic Receives New Indications in Chronic Kidney Disease Semaglutide is now approved for reducing the risk for worsening kidney disease and ...

Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new research shows. Compared to another ...

Share on Pinterest The FDA approved Ozempic to help lower chronic kidney disease-related risks in people with type 2 diabetes. urbazon/Getty Images The Food and Drug Administration (FDA ...

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...